Aria CV, Inc.

Congratulations to Drs. Eileen Harder, Jane Leopold, Aaron Waxman and Edwin Gravereaux, and the team at Brigham and Women's Hospital and Women’s Hospital for implanting their second patient in the ASPIRE PH Study with the Gen 2 Aria CV Pulmonary Hypertension System. This is the first implant for Brigham and Women’s Hospital with the Gen 2 Aria System. The team previously enrolled the very first patient in the ASPIRE PH Study using the Gen 1 device. Aria CV appreciates their dedication to ongoing research for the treatment of pulmonary hypertension and their collaboration with the Aria CV team. Continue to follow #AriaCV to learn more about #rvfailure, compliance, and the Aria CV Pulmonary Hypertension System to treat #pulmonaryhypertension and #rightheartdysfunction.

Since the 1980s, long-term survival rates for people with pulmonary hypertension have improved significantly, surpassing the previous average of 2.8 years. This improvement is largely due to advancements in research, treatment and care, increased awareness, and the support of patient associations. Specialized PH care centers also play a critical role in providing comprehensive care and improving patient outcomes. #AriaCV is proud to play a role in researching treatment options that give hope to those affected by PH. #WorldPHDay2024

Exciting News! Aria CV announces the publication of clinical results from its Acute Assessment of the Aria CV System in Patient with WHO Groups 2 and 3 Pulmonary Hypertension study. #ariacv #pulmonaryhypertension #rightheartfailure #rightheartdysfunction https://lnkd.in/g3DCdvGp

Stop by #CRT2024 March 11th to learn more about the Aria CV Pulmonary Hypertension System and early results from the ASPIRE PH Trial.  We look forward to connecting with you. #Ariacv #pulmonaryhypertension #rightheartdysfunction

We look forward to engaging with attendees at the #CRT2024 Annual Conference this month as they highlight new cardiovascular technologies and procedures for physicians and health-care professionals. #Ariacv is committed to developing medical devices that improve the lives of patients living with #pulmonaryhypertension and #rightheartdysfunction. Visit us at CRT to learn more.

Did you know that February 29th, is Rare Disease Day? On this day the Pulmonary Hypertension Association joins the National Organization of Rare Disorders (and countless other organizations) to raise awareness and bring attention to conditions that are often underdiagnosed or mislabeled, like pulmonary hypertension. There is no cure for pulmonary hypertension, there is hope for the future through ongoing research and available treatments. Continue to follow #AriaCV to learn more about #rvfailure, compliance, and the Aria CV Pulmonary Hypertension System to treat #pulmonaryhypertension and #rightheartdysfunction.

Congratulations to Drs. Ashwin Ravichandran and Scott Hittinger and the team at Ascension St. Vincent Cardiovascular Research Institute for implanting the first patient with the Gen 2 Aria CV Pulmonary Hypertension System. Continue to follow #AriaCV to learn more about #rvfailure, compliance, and the Aria CV Pulmonary Hypertension System to treat #pulmonaryhypertension and #rightheartdysfunction.

Pulmonary hypertension is a complex, rare disease that can be associated with other rare conditions. Spread awareness about PH and its associated diseases during #PHAwarenessMonth in November. #AriaCV #pulmonaryhypertension

November is Pulmonary Hypertension Awareness Month! Common Pulmonary Hypertension symptoms include breathlessness, fatigue, dizziness, fainting, chest pain and swelling in the arms and legs. #ariacv #pulmonaryhypertension #PHAawarenessmonth